CGRP Peptide's Dual Role in Osteoarthritis: Driving Joint Inflammation While Also Aiding Cartilage Repair

This is a narrative review that synthesizes current evidence on CGRP's roles in osteoarthritis-affected tissues. The authors first review the fundamental physiology and pathology of CGRP in cartilage, then summarize evidence from multiple studies on CGRP in OA, and finally examine potential therapeutic strategies for targeting CGRP to promote cartilage regeneration.

Osteoarthritis is the most common joint disease worldwide and a leading cause of disability in older adults, yet there are no disease-modifying drugs — only treatments that manage symptoms. The discovery that CGRP has both harmful (inflammatory) and helpful (regenerative) effects in joints is significant because anti-CGRP drugs already exist for migraine. Understanding these dual roles is essential before repurposing migraine drugs for OA, and could lead to entirely new therapeutic strategies based on selective CGRP modulation.

The success of anti-CGRP antibodies for migraine has raised questions about what happens when this peptide is blocked long-term throughout the body. CGRP is expressed in many tissues beyond the brain, including joints, bones, and blood vessels. This review highlights a potential concern: while blocking CGRP reduces migraine pain, it could theoretically impact cartilage health in joints. Conversely, it opens the intriguing possibility that targeted CGRP modulation could address OA — a disease with enormous unmet medical need. The overlap between the migraine and OA research communities is a developing area.

This is a narrative review that synthesizes existing literature without performing systematic analysis or meta-analysis. The evidence for CGRP's regenerative role in cartilage is still emerging and largely from preclinical studies. The optimal approach to CGRP modulation in OA (blocking vs. enhancing vs. targeted delivery) is theoretical and untested in clinical trials. The relationship between CGRP-mediated inflammation and cartilage damage may vary across different OA subtypes and disease stages.